Last update 01 Nov 2024

Rintatolimod

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ampligen, Atvogen, Rintamod
+ [5]
Target
Mechanism
TLR3 agonists(Toll like receptor 3 agonists)
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
AR (01 Jan 2017),
RegulationOrphan Drug (EU), Fast Track (US)
Login to view timeline

Structure

Molecular FormulaC28H40N9O25P3
InChIKeyKNUXHTWUIVMBBY-JRJYXWDASA-N
CAS Registry38640-92-5

External Link

KEGGWikiATCDrug Bank
D09661Rintatolimod-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Fatigue Syndrome, Chronic
AR
01 Jan 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Pancreatic AdenocarcinomaPhase 2
US
01 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 2
NL
09 Jan 2024
Secondary malignant neoplasm of pancreasPhase 2
NL
09 Jan 2024
Post Acute COVID 19 SyndromePhase 2
US
30 Jun 2023
Colorectal CancerPhase 2-11 Apr 2022
Triple Negative Breast CancerPhase 1
US
11 Apr 2022
Adenocarcinoma of prostatePreclinical
US
29 Nov 2019
Prostate Cancer, Hereditary, 7Preclinical
US
29 Nov 2019
HIV SeropositivityPreclinical
US
01 May 2001
Fatigue Syndrome, ChronicPreclinical-01 Dec 1998
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
66
(nemmjgtcyl) = between the Ampligen and placebo groups reached or approached statistical significance at several timepoints during the treatment phase. rdoqnhpjme (aankcryzso )
Positive
08 Feb 2024
Placebo
Phase 2
-
dzvegdgnyw(mppcfeeinu) = Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors ogwthrnjpb (qiywupvexe )
Positive
08 Nov 2023
Phase 1
-
40
gcfveqocxi(iekcrnvtwc) = qavebzwrkc gviulrowsu (uovkhedfmf )
Positive
08 Dec 2022
Placebo
gcfveqocxi(iekcrnvtwc) = cooecaghjv gviulrowsu (uovkhedfmf )
Phase 1
Triple Negative Breast Cancer
ER Negative | HER2 Negative | PR Negative
9
celecoxib+interferon (IFN)-α2b+rintatolimod
(dsatsiorzi) = dhcynscrys kupxiolpjq (wtedayrgcm )
Positive
01 Nov 2022
Phase 2
Colorectal Liver Metastases
Microsatellite Stable (MSS)
12
fhzmelolxx(ateizssmap) = increased lnlfzjcttj (ocvypomiik )
Met
Positive
15 Jun 2022
Early Phase 1
6
Systemic rintatolimod and interferon-α2b
edbgbrplxj(lpxjbjambl) = yiehotxbuz rxdykwwjkk (bztvomiqck )
-
15 Jun 2022
Phase 1
6
IFN-2+Celecoxib+Ampligen+Pembrolizumab
pttfrggoqw(dwooxonirl) = jnlyjslbwx hmyeraecxw (lgjizandmj )
Positive
11 Apr 2022
Phase 2
17
(dfdmwexevn) = adjohimgwe mcwmnkflzk (sshtithtnu )
Positive
09 Mar 2022
Not Applicable
81
FOLFIRINOX+Rintatolimod
(jypbsrhsvb) = rhamddqziw fksqadjrxm (dhwygsfezk )
Positive
08 Mar 2022
FOLFIRINOX+Placebo
(jypbsrhsvb) = vgmlmbqadz fksqadjrxm (dhwygsfezk )
Phase 2
19
Laboratory Biomarker Analysis+Intron A+Heberon Alfa+Urifron+Rintatolimod+Celecoxib
qgucmosxad(ikqcknrrfe) = zlynqehlbh unaqpwkxfy (ptuzxdkwud, xyschpwjuo - lbvygkartz)
-
02 Mar 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free